OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 01:05 UTC. Every row links to its source record.

ARID5B AT-rich interaction domain 5B

ENSG00000150347 · protein coding · Open Targets profile

Transcription coactivator that binds to the 5'-AATA[CT]-3' core sequence and plays a key role in adipogenesis and liver development. Acts by forming a complex with phosphorylated PHF2, which mediates demethylation at Lys-336, leading to target the PHF2-ARID5B complex to target promoters, where PHF2 mediates demethylation of dimethylated 'Lys-9' of histone H3 (H3K9me2), followed by transcription activation of target genes. The PHF2-ARID5B complex acts as a coactivator of HNF4A in liver. Required for adipogenesis: regulates triglyceride metabolism in adipocytes by regulating expression of adipogenic genes. Overexpression leads to induction of smooth muscle marker genes, suggesting that it may also act as a regulator of smooth muscle cell differentiation and proliferation. Represses the cytomegalovirus enhancer. .

In 14 of 15 cancers, the evidence for ARID5B comes mainly from inherited variants

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751acute lymphoblastic leukemiaacute lymphoblastic leukemiaacute lymphoblastic leukemia: germline 0.82B-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemia: germline 0.80reticulum cell sarcomareticulum cell sarcomareticulum cell sarcoma: germline 0.54childhood acute lymphoblastic leukemiachildhood acute lymphoblastic leukemiachildhood acute lymphoblastic leukemia: germline 0.54breast carcinomabreast carcinomabreast carcinoma: germline 0.20breast cancerbreast cancerbreast cancer: germline 0.17breast neoplasmbreast neoplasmbreast neoplasm: germline 0.16estrogen-receptor negative breast cancerestrogen-receptor negative breast cancerestrogen-receptor negative breast cancer: germline 0.16estrogen-receptor positive breast cancerestrogen-receptor positive breast cancerestrogen-receptor positive breast cancer: germline 0.14luminal B breast carcinomaluminal B breast carcinomaluminal B breast carcinoma: germline 0.11ductal breast carcinoma in situductal breast carcinoma in situductal breast carcinoma in situ: germline 0.09breast cystbreast cystbreast cyst: germline 0.09Her2-receptor negative breast cancerHer2-receptor negative breast cancerHer2-receptor negative breast cancer: germline 0.09hereditary multiple exostoseshereditary multiple exostosesluminal A breast carcinomaluminal A breast carcinomaluminal A breast carcinoma: germline 0.08

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Antibody
Human Protein Atlas loc
PROTAC
UniProt Ubiquitination, Database Ubiquitination

gnomAD loss of function constraint: o/e 0.13369999825954437 (upper bound 0.21256999671459198). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of ARID5B's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of ARID5B's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.